Lund LH, et al. - Candesartan was hypothesized to improve outcomes in heart failure (HF) with mid-range ejection fraction [HFmrEF; ejection fraction (EF) 40–49%]. This hypothesis was tested by researchers via examining characteristics, outcomes and treatment effect of candesartan according to EF in patients enrolled in the CHARM Programme (HF across the spectrum of EF). The primary outcome was cardiovascular death or HF hospitalization. With EF as a continuous spline variable, a significant attenuation in the primary outcome was seen with candesartan until EF well over 50%. A similar reduction was seen for recurrent HF hospitalizations until EF well over 60%. Overall, outcome improvement brought about by candesartan in HFmrEF was noted to be of a similar degree as has been observed in HF with reduced EF.